Voting Common Stock, par value $0.0001 per share
- Symbol
- JSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Jasper Therapeutics, Inc.
JSPRNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”).…
Company context
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
Current securities
Registered securities in this filing
JASPER THERAPEUTICS, INC. · 8-K · Filed 2026-10-05
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special
Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common stock, $0.0001 par value per
share (the “Common Stock”), or approximately 65.36% of the 33,274,561 shares of the Common Stock issued and outstanding as
of August 10, 2026, the record date for the Special Meeting, were represented virtually or by proxy.
At
the Special Meeting, the Company’s stockholders considered three proposals, each of which is described in more detail in the Company’s
definitive proxy statement filed with the Securities and Exchange Commission on September 4, 2026.
Set
forth below is a brief description of each proposal voted upon at the Special Meeting and the voting results with respect to each
proposal. Each proposal was approved at the Special Meeting.
Proposal
No. 1: To approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended (the
“Certificate of Incorporation”), to effect, in the sole discretion of the Company’s Board of Directors (the “Board”)
at any time on or before December 31, 2026, a reverse stock split of the Common Stock, at a ratio to be determined by the Board within
a range of 1-for-15 to 1-for-35 (or any number in between), without reducing the authorized number of shares of Common Stock, and without
further approval or authorization of the Company’s stockholders (the “Reverse Stock Split Proposal”).
Votes Votes Abstentions Broker
For Against Non-Votes
───────────────────────────────────────────────────────────
21,088,353 567,692 91,820 –
Proposal
No. 2: To approve an amendment to the Certificate of Incorporation to increase the total number of authorized shares of Common Stock
from 490,000,000 shares to 675,000,000 shares, to be effected in the sole discretion of the Board (the “Authorized Share Increase
Proposal”).
Votes Votes Abstentions Broker
For Against Non-Votes
───────────────────────────────────────────────────────────
20,722,644 903,655 121,566 –
Proposal
No. 3: To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there were not sufficient
votes in favor of the Reverse Stock Split Proposal or the Authorized Share Increase Proposal (the “Adjournment Proposal”).
Votes Votes Abstentions Broker
For Against Non-Votes
───────────────────────────────────────────────────────────
20,938,915 528,123 280,827 –